Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Myofibroma × remimazolam × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Quality of Recovery 1 Myofibroma 1 Endobronchial Metastases 1

Interventions

Saline Solution 3 Uterine Artery Embolization 2 Tourniquets 2 Misoprostol 2 Lidocaine 2 ulipristal 1 telapristone acetate 1 remimazolam 1 relugolix 1 pirfenidone 1 estradiol, norethindrone drug combination 1 dienogest 1 carbetocin 1 Vasopressins 1 Uterine Myomectomy 1 Triptorelin Pamoate 1 Sodium Chloride 1 Sevoflurane 1 Respiration, Artificial 1 Remifentanil 1 Propofol 1 Population Groups 1 Morcellation 1 Leuprolide 1 Laparoscopy 1 LFA102 monoclonal antibody 1 Hysterectomy 1 Dinoprostone 1 Dexamethasone 1 Desflurane 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05025410 2022-04-25

Remimazolam and Remifentanil Without Neuromuscular Blocking Agent

Seoul National University Bundang Hospital

Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡